Asparaginase: A hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC 3.5.1.1.Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.Asparagine: A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from ASPARTIC ACID and AMMONIA by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed)Erwinia: A genus of gram-negative, facultatively anaerobic, rod-shaped bacteria whose organisms are associated with plants as pathogens, saprophytes, or as constituents of the epiphytic flora.Drug Hypersensitivity: Immunologically mediated adverse reactions to medicinal substances used legally or illegally.Aspartate-Ammonia Ligase: An enzyme that catalyzes the formation of asparagine from ammonia and aspartic acid, in the presence of ATP. EC 6.3.1.1.Dimethyldithiocarbamate: A chemical that acts as a dopamine beta-hydroxylase inhibitor. Its salts are agricultural fungicides. It is inferior to diethyldithiocarbamate as a chelating agent.Leukemia L5178: An experimental lymphocytic leukemia of mice.Lactate dehydrogenase-elevating virus: A species ARTERIVIRUS, occurring in a number of transplantable mouse tumors. Infected mice have permanently elevated serum levels of lactate dehydrogenase.Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.GlutaminaseInjections, Intramuscular: Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it.Aspartate Ammonia-Lyase: An enzyme that catalyzes the conversion of aspartic acid to ammonia and fumaric acid in plants and some microorganisms. EC 4.3.1.1.Polyethylene Glycols: Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.Cytarabine: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)Remission Induction: Therapeutic act or process that initiates a response to a complete or partial remission level.Vincristine: An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)Encyclopedias as Topic: Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)EncyclopediasDictionaries, MedicalDictionaries as Topic: Lists of words, usually in alphabetical order, giving information about form, pronunciation, etymology, grammar, and meaning.Pectobacterium chrysanthemi: A species of gram-negative, facultatively anaerobic, rod-shaped bacteria that causes vascular wilts on a wide range of plant species. It was formerly named Erwinia chrysanthemi.Societies, Pharmaceutical: Societies whose membership is limited to pharmacists.Polysaccharide-Lyases: A group of carbon-oxygen lyases. These enzymes catalyze the breakage of a carbon-oxygen bond in polysaccharides leading to an unsaturated product and the elimination of an alcohol. EC 4.2.2.Internship, Nonmedical: Advanced programs of training to meet certain professional requirements in fields other than medicine or dentistry, e.g., pharmacology, nutrition, nursing, etc.Chicory: A thick-rooted perennial (Cichorium intybus) native to Europe but widely grown for its young leaves used as salad greens and for its roots, dried and ground-roasted, used to flavor or adulterate coffee. (From Webster, 3d ed)Libraries, Digital: Libraries in which a major proportion of the resources are available in machine-readable format, rather than on paper or MICROFORM.Cyclic AMP: An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH.Culture Media: Any liquid or solid preparation made specifically for the growth, storage, or transport of microorganisms or other types of cells. The variety of media that exist allow for the culturing of specific microorganisms and cell types, such as differential media, selective media, test media, and defined media. Solid media consist of liquid media that have been solidified with an agent such as AGAR or GELATIN.Escherichia coli Proteins: Proteins obtained from ESCHERICHIA COLI.Ammonium Sulfate: Sulfuric acid diammonium salt. It is used in CHEMICAL FRACTIONATION of proteins.Ammonia: A colorless alkaline gas. It is formed in the body during decomposition of organic materials during a large number of metabolically important reactions. Note that the aqueous form of ammonia is referred to as AMMONIUM HYDROXIDE.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Chryseobacterium: A genus of aerobic, gram-negative bacteria in the family FLAVOBACTERIACEAE. Many of its species were formerly in the genus FLAVOBACTERIUM.Flavobacteriaceae Infections: Infections with bacteria of the family FLAVOBACTERIACEAE.Flavobacteriaceae: A family of bacteria in the order Sphingobacteriales, class Sphingobacteria. They are gram-negative rods, mostly saprophytic in terrestrial and aquatic habitats.Aspartylglucosaminuria: A recessively inherited, progressive lysosomal storage disease caused by a deficiency of GLYCOSYLASPARAGINASE activity. The lack of this enzyme activity results in the accumulation of N-acetylglucosaminylasparagine (the linkage unit of asparagine-linked glycoproteins) in LYSOSOMES.Oligosaccharides: Carbohydrates consisting of between two (DISACCHARIDES) and ten MONOSACCHARIDES connected by either an alpha- or beta-glycosidic link. They are found throughout nature in both the free and bound form.Sulfolobus acidocaldarius: A species of aerobic, chemolithotrophic ARCHAEA consisting of coccoid cells that utilize sulfur as an energy source. The optimum temperature for growth is 70-75 degrees C. They are isolated from acidic fields.Archaea: One of the three domains of life (the others being BACTERIA and Eukarya), formerly called Archaebacteria under the taxon Bacteria, but now considered separate and distinct. They are characterized by: (1) the presence of characteristic tRNAs and ribosomal RNAs; (2) the absence of peptidoglycan cell walls; (3) the presence of ether-linked lipids built from branched-chain subunits; and (4) their occurrence in unusual habitats. While archaea resemble bacteria in morphology and genomic organization, they resemble eukarya in their method of genomic replication. The domain contains at least four kingdoms: CRENARCHAEOTA; EURYARCHAEOTA; NANOARCHAEOTA; and KORARCHAEOTA.Sulfolobus solfataricus: A species of thermoacidophilic ARCHAEA in the family Sulfolobaceae, found in volcanic areas where the temperature is about 80 degrees C and SULFUR is present.Gram-Negative Chemolithotrophic Bacteria: A large group of bacteria including those which oxidize ammonia or nitrite, metabolize sulfur and sulfur compounds, or deposit iron and/or manganese oxides.Sulfolobus: A genus of aerobic, chemolithotrophic, coccoid ARCHAEA whose organisms are thermoacidophilic. Its cells are highly irregular in shape, often lobed, but occasionally spherical. It has worldwide distribution with organisms isolated from hot acidic soils and water. Sulfur is used as an energy source.Algorithms: A procedure consisting of a sequence of algebraic formulas and/or logical steps to calculate or determine a given task.AmidohydrolasesHelicobacter pylori: A spiral bacterium active as a human gastric pathogen. It is a gram-negative, urease-positive, curved or slightly spiral organism initially isolated in 1982 from patients with lesions of gastritis or peptic ulcers in Western Australia. Helicobacter pylori was originally classified in the genus CAMPYLOBACTER, but RNA sequencing, cellular fatty acid profiles, growth patterns, and other taxonomic characteristics indicate that the micro-organism should be included in the genus HELICOBACTER. It has been officially transferred to Helicobacter gen. nov. (see Int J Syst Bacteriol 1989 Oct;39(4):297-405).Helicobacter Infections: Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.Helicobacter: A genus of gram-negative, spiral-shaped bacteria that has been isolated from the intestinal tract of mammals, including humans. It has been associated with PEPTIC ULCER.Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.

Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia. (1/487)

PURPOSE: The CNS is an important sanctuary site in childhood acute lymphoblastic leukemia (ALL). CSF asparagine concentration reflects asparaginase systemic pharmacodynamics. We evaluated the time course of CSF asparagine depletion in children with ALL during and after a course of Escherichia coli asparaginase. PATIENTS AND METHODS: Thirty-one children (24 newly diagnosed and seven at relapse) received E coli asparaginase 10,000 IU/m2 intramuscularly three times weekly for six and nine doses, respectively, as part of multiagent induction chemotherapy. CSF asparagine levels were measured before, during, and after asparaginase dosing. RESULTS: The percentage of patients with undetectable (< 0.04 micromol/L) CSF asparagine was 3.2% (one of 31 patients) at baseline, 73.9% (17 of 23) during asparaginase therapy, and 56.3% (nine of 16) 1 to 5 days, 43.8% (seven of 16) 6 to 10 days, 20.0% (two of 10) 11 to 30 days and 0% (zero of 21) more than 30 days after asparaginase therapy. The proportion of patients with depleted CSF asparagine was higher during asparaginase therapy than at baseline (P < .001), 11 to 30 days (P = .003), and more than 30 days after asparaginase therapy (P < .001). Median CSF asparagine concentrations were 4.42 micromol/L before, less than 0.04 micromol/L during, and less than 0.04 micromol/L at 1 to 5 days, 1.63 micromol/L at 6 to 10 days, 1.70 micromol/L at 11 to 30 days, and 5.70 micromol/L at more than 30 days after asparaginase therapy, respectively. CSF depletion was more common in patients with low baseline CSF asparagine concentrations (P = .003). CONCLUSION: CSF asparagine concentrations are depleted by conventional doses of E coli asparaginase in the majority of patients, but they rebound once asparaginase therapy is completed.  (+info)

Long-term follow-up results of adult patients with acute lymphocytic leukemia or lymphoblastic lymphoma treated with short-term, alternating non-cross-resistant chemotherapy: Japan Clinical Oncology Group Study 8702. Lymphoma Study Group. (2/487)

BACKGROUND: Patients with acute lymphocytic leukemia (ALL) and those with lymphoblastic lymphoma (LBL) have overlapping clinical and immunophenotypic features and they have been treated with the same or very similar chemotherapy regimens. The goal of this multi-institutional phase II trial was to evaluate the therapeutic efficacy of a short-term, six-drug chemotherapy regimen for adult patients with untreated ALL or LBL. METHODS: Forty-six eligible patients, 41 with ALL and five with LBL, were treated with a short-term (planned total therapy duration; 36-38 weeks), simplified chemotherapy program; two courses of VEPA-L (vincristine, cyclophosphamide, prednisolone, doxorubicin, I-asparaginase plus intrathecal methotrexate and prednisolone) followed by four courses of M-VEPA (methotrexate plus VEPA), without the traditional maintenance therapy using daily 6-mercaptopurine and weekly methotrexate. RESULTS: Thirty-six (78%; 95% confidence interval 64-89%) of the 46 eligible patients achieved complete remission (CR). Among the 36 patients who achieved CR, four (11%) died of treatment complications, 26 (72%) relapsed and six (17%) remain alive in continuous CR. The median survival for all 46 eligible patients is 14 months and the median disease-free survival (DFS) for the 36 patients who achieved CR is 11 months. The estimate of the proportion of survival at 7 years of all 46 eligible patients is 15% at a median follow-up time of 96 months and that of DFS of the 36 patients achieving CR is 17% at a median follow-up time of 93 months. Subgroup analysis showed that an elevated serum C-reactive protein (CRP) level, age of 30 years or older, the presence of B-symptom and T-cell phenotype were likely to be associated with shortened survival. Although the observed CR rate (78%) is within the range of satisfaction, the long-term survival rate (15%) is inferior to those of published programs incorporating maintenance therapy. CONCLUSIONS: A fraction of adult patients with ALL or LBL are curable with a short-term, six-drug chemotherapy regimen. However, this simplified therapy of shorter duration cannot be recommended.  (+info)

Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study. (3/487)

BACKGROUND AND OBJECTIVE: In a prior study, primary resistant acute lymphoblastic leukemia (RES-ALL) was observed in 11 of 176 (6%) adult patients treated with a four drug regimen (IVAP), its incidence being higher in T-cell or Philadelphia (Ph) chromosome/BCR-ABL rearrangement positive ALL cases with a blast cell count >25x10(9)/L (RES-ALL rate 19%, p=0.04). Aiming to minimize this percentage of resistant disease, fractionated cyclophosphamide (f-CY) was then added to the IVAP regimen. DESIGN AND METHODS: Study 08-96 was a prospective, collaborative phase II trial carried out at eight general hospital centers specialized in the care of hematologic malignancies. Historical IVAP-treated patients served as a retrospective control group. All consecutive, untreated patients (>15 years) with a diagnosis of ALL or advanced-stage lymphoblastic lymphoma (LBL) were eligible. RES-ALL was defined as the persistence of >5% ALL cells in the bone marrow 28-40 days after the start of the IVAP regimen (idarubicin 10 mg/m(2)/d on days 1 and 2; vincristine 2 mg on days 1, 8 and 15; L-asparaginase 6,000 U/m(2) on alternate days 3 6 from day 8; prednisone 60 mg/m(2)/d on days 1-21). In the new study, two f-CY schedules were sequentially adopted: CY 150 or 75 mg/m(2)/bd, given for 4 consecutive days before IVAP (f-CY 1200 or 600, expressing total CY dose in mg/m(2)). RESULTS: Eighty-eight patients were evaluable (age range 15-74 years, blast count 0-240x10(9)/L, 14 T-lineage, 74 B-lineage, 13 Ph/BCR-ABL+). The first 39 patients received the f-CY 1200 schedule, 22 patients received f-CY 600, and the last 27 patients were not given any f-CY. These changes were dictated by the results of interim analyses of the f-CY groups (RES-ALL rate not reduced, myelotoxicity increased). Altogether, compared with the historical IVAP and no f-CY groups, the incidence of RES-ALL was not decreased by the addition of f-CY 1200/600 in B-lineage ALL, regardless of Ph/BCR-ABL expression and blast count. However, none of 14 T-ALL cases in the new study had RES-ALL (8 in f-CY groups, 5 of whom with >25x10(9)/L blast cells), compared to 5/39 (13%, overall) or 4/21 (19%, with >25x10(9)/L blast cells) among the control cases. Owing to small sample size, this difference was not statistically significant. INTERPRETATION AND CONCLUSIONS: This preliminary experience suggests that T-ALL may be more sensitive than B-lineage ALL to an early therapy including f-CY. The hypothesis could be tested in a larger clinical trial.  (+info)

Non-Hodgkin's lymphoma in children: results of treatment with LSA2-L2 protocol. (4/487)

The results obtained with very intensive treatment in previously untreated patients early in the disease are encouraging, and we hope will change the philosophy of most investigators that even in far advanced disease such as those with marrow metastases or multiple primary sites, one can still obtain complete regression at all tumour sites within 1 to 1 1/2 months from onset of therapy by combined treatment with multiple chemotherapeutic agents and radiation therapy to one or more sites.  (+info)

Acute lymphoblastic leukaemia: cyclical chemotherapy with three combinations of four drugs (COAP-POMP-CART regimen). (5/487)

Forty-two adults and children with previously untreated acute lymphoblastic leukaemia (ALL) were entered into a programme of chemotherapy in which three combinations, each of four drugs were administered in a predetermined cyclical rotation together with cranial irradiation and intrathecal injections of methotrexate. Forty-one patients (98%) entered remission and no patient developed neuroleukaemia. Relapse of ALL occurred in 10 patients, and three patients died during remission, while eight patients stopped treatment after two and a half years and have remained in remission for two to 26 months. Comparison of remission and survival experience in this mixed group of children and adults with the experience of children treated at Memphis and in the Medical Research Council's UKALL-I trial showed no significant differences. On the other hand, analysis by prognostic factors showed that neither age nor blast cell count at presentation had any adverse effect in patients treated in this study. No relapses occurred in nine patients with blast cell counts greater than 20 x 109/1 at presentation. This regimen is effective treatment for ALL and may be of special value in patients with poor prognoses. The regiment has not as yet proved superior for the treatment of children with ALL who do not have adverse prognostic features.  (+info)

Applications of synchrotron radiation to protein crystallography: preliminary results. (6/487)

X-ray diffraction photographs of protein single crystals have been obtained using synchrotron radiation produced by an electron-positron storage ring. The diffracted intensities observed with this unconventional source are a factor of at least 60 greater than those obtained with a sealed x-ray tube using the same crystal and instrumental parameters. Diffraction data have been collected by the precession method to higher resolution and using smaller protein crystals than would have been possible with a conventional source. The crystal decay rate in the synchrotron beam for several proteins appears to be substantially less than that observed with Ni-filtered Cu radiation. The tunable nature of the source (which allows selective optimization of anomalous contributions to the scattering factors) and the low angular divergence of the beam make the source very useful for single crystal protein diffraction studies.  (+info)

Hypersensitivity to tobacco antigen. (7/487)

A glycoprotein of molecular weight 18,000 was purified from saline extracts of cured tobacco leaves by ammonium sulfate fractionation, chromatography on Sephadex G-25 and continuous-flow preparative electrophoresis on polyacrylamide gel. Twelve of 31 volunteers (6/15 smokers and 6/16 nonsmokers) exhibited immediate cutaneous hypersensitivity (wheal and flare reactions) when injected intracutaneously with 2 mug of this material. Immunochemically similar material was demonstrated in, and purified from, cigarette smoke condensate and cigarette smoke. The concentration in cigarette smoke condensate ("tar") was determined to be 1.8-3.6 mg/g. Antigenically crossreactive material was also demonstrated in eggplants, green peppers, potatoes, and tomatoes, which, like tobacco, are members of the family Solanaceae.  (+info)

Binding of Clostridium botulinum C2 toxin to asparagine-linked complex and hybrid carbohydrates. (8/487)

Clostridium botulinum C2 toxin is a binary toxin composed of an enzymatic subunit (C2I) capable of ADP-ribosylating actin and a binding subunit (C2II) that is responsible for interaction with receptors on eukaryotic cells. Here we show that binding of C2 toxin depends on the presence of asparagine-linked carbohydrates. A recently identified Chinese hamster ovary cell mutant (Fritz, G., Schroeder, P., and Aktories, K. (1995) Infect. Immun. 63, 2334-2340) was found to be deficient in N-acetylglucosaminyltransferase I. C2 sensitivity of this mutant was restored by transfection of an N-acetylglucosaminyltransferase I cDNA. C2 toxin sensitivity was reduced after inhibition of alpha-mannosidase II. In contrast, Chinese hamster ovary cell mutants deficient in sialylated (Lec2) or galactosylated (Lec8) glycoconjugates showed an increase in toxin sensitivity compared with wild-type cells. Our results show that the GlcNAc residue linked beta-1,2 to the alpha-1,3-mannose of the asparagine-linked core structure is essential for C2II binding to Chinese hamster ovary cells.  (+info)

Abstract: We have studied dose- and time-dependent antitumor and cytotoxic effects of Erwinia carotovora L-asparaginase (ECAR LANS) and Escherichia coli L-asparaginase (MEDAC) on human leukemic cells and human and animal solid tumor cells. We determined the sensitivity of tumor cells to L-asparaginases, as well the effect L-asparaginases on cell growth rate, protein and DNA synthesis per se and with addition of different cytostatics. The data obtained demonstrated that ECAR LANS L-asparaginase suppressed growth of all tested solid tumor cells. Evaluation of leukemic cell number after treatment with L-asparaginases for 24, 48 and 72 h demonstrated that asparagine deficiency did not kill cells but stopped normal cell division and had no effect on protein and DNA synthesis. Cytofluorometric study of solid and leukemic cells demonstrated that the treatment with L-asparaginase for 72 h did not change cell cycle phase distribution and did not increase the number of apoptotic cells. The HL-60 cell line ...
Asparaginase is one of the key therapeutic agents for childhood acute lymphoblastic leukemia (ALL) [ 1 ]. Asparaginase is an active bacterial enzyme
Growth of Escherichia coli A-l under aerobic conditions in an enriched medium with a total amount of 0.2 per cent glucose was biphasic and asparaginase II activity was detected after depletion of ammonia from the growth medium in the second phase of growth. Glucose was exhausted two hours before ammonia and three hours before asparaginase II activity was detected. The concentration of 3,5-cyclic adenosine monophosphate was found to fluctuate when the dissolved oxygen in the medium reached a low level, when glucose and ammonia were exhausted, and when the cells entered the second stationary phase of growth. Culture tube studies of the growth of E_j_ coli A-l in three per cent nutrient broth with varied concentrations of ammonium chloride and potassium nitrate gave lower specific activity of asparaginase II when this was compared to that seen in three per cent nutrient broth alone. The addition of glucose to the same medium before asparaginase II activity was detected resulted in the production of acid
Hypersensitivity to pegaspargase is associated with inferior survival in pediatric patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. In the past year, drug-supply shortages have led to the lack of an available alternative to pegaspargase. Rather than omit asparaginase from the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma patients with hypersensitivity to pegaspargase, we continued pegaspargase treatments for nine pediatric patients, utilizing a rapid desensitization protocol. There were no adverse events related to the pegaspargase during desensitization, and all patients who were checked had asparaginase serum levels above the threshold of 0.1 IU/mL at 7 to 14 days after pegaspargase therapy.
l -asparaginase (L-ase) is a major drug used to treat acute lymphoblastic leukemia (ALL) [1]. L-ase kills leukemic cells by depleting circulating asparagine pools related to its asparaginase activity [2]. L-ases from Escherichia coli and Erwinia chrysanthemi also degrade l -glutamine due to their glutaminase activity. Th e primary adverse eff ects of L-ase include hypersensitivity, thrombosis, immunosuppression and cytotoxic eff ects. L-ase also induces liver dysfunction with macroand microvesicular steatosis, which may rapidly lead to liver failure, coma and death [3 - 6]. L-ase-induced liver defects are related to decreased protein synthesis due to a reduction in asparagine and glutamine pools [7,8]. Microvesicular steatosis is the most severe form of liver steatosis and is caused by impairment of mitochondrial β -oxidation, leading to the accumulation of unoxidized fatty acids converted to triglycerides [9]. Th is change is often accompanied or dominated by macrovesicular steatosis, as observed with
Get information, facts, and pictures about Asparaginase at Encyclopedia.com. Make research projects and school reports about Asparaginase easy with credible articles from our FREE, online encyclopedia and dictionary.
Bacterial asparaginases (amidohydrolases, EC 3.5.1.1) are important enzymes in cancer therapy, especially for Acute Lymphoblastic Leukemia. They are tetrameric enzymes able to catalyze the deamination of L-ASN and, to a variable extent, of L-GLN, on which leukemia cells are dependent for survival. In contrast to other known L-asparaginases, Helicobacter pylori CCUG 17874 type II enzyme (HpASNase) is cooperative and has a low affinity towards L-GLN. In this study, some critical amino acids forming the active site of HpASNase (T16, T95 and E289) have been tackled by rational engineering in the attempt to better define their role in catalysis and to achieve a deeper understanding of the peculiar cooperative behavior of this enzyme. Mutations T16E, T95D and T95H led to a complete loss of enzymatic activity. Mutation E289A dramatically reduced the catalytic activity of the enzyme, but increased its thermostability. Interestingly, E289 belongs to a loop that is very variable in L-asparaginases from the
Angiolillo, A.L., Schore, R.J., Devidas, M., Borowitz, M.J., Carroll, A.J. et al. (2014). Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Childrens Oncology Group Study AALL07P4. Journal of Clinical Oncology, 32(34), 3874-3882.. ...
When you donate blood or platelets at the Kraft Family Blood Donor Center at Dana-Farber Cancer Institute and Brigham and Women's Hospital, or give blood on board the Dana-Farber Cancer Institute/Brigham and Women's Hospital Blood Mobile, you are making a life-saving difference for patients in need - right here in our community.
The antileukemic activity of l-asparaginase (ASNase), an important component of therapy for acute lymphoblastic leukemia, is thought to result from depletion of serum l-asparagine (Asn). In studies of the pharmacological effects of ASNase, investigators have reported prolonged reduction in the serum concentration of Asn after the administration of ASNase. Such measurements may not be valid because ASNase present in the blood sample may hydrolyze Asn before its determination. We examined recovery of [U-14C]Asn from blood samples with and without various concentrations of added ASNase. In the presence of ≥0.01 IU/ml of ASNase, the amount of [U-14C]Asn recovered was ,15% of that without ASNase. Utilizing this assay, we studied the effect of 2 known inhibitors of ASNase in an attempt to improve Asn recovery. In the presence of aspartic β semialdehyde (ASA), or 5-diazo-4-oxo-l-norvaline (DONV), and up to 1.0 IU/ml ASNase, Asn levels remained at ,90% of control. ASA prevented the hydrolysis of ...
Dana-Farber employs more than 4,274 full-time and part-time people, 467 faculty, and has annual gross revenues of about $1,086,638,000.[1] There are more than 299,202 adult and pediatric patient visits a year, and it is involved in more than 700 clinical trials. It is internationally known for its research and clinical excellence. Expertscape ranks its programs in aplastic anemia[2] and multiple myeloma[3] as best in the world. It has been also ranked the fourth best cancer hospital in the United States by U.S. News & World Report.[4] Dana-Farber is a member of the Multiple Myeloma Research Consortium. In addition to being a principal teaching affiliate of Harvard Medical School, Dana-Farber is also a federally designated Center for AIDS Research, and a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC),[5] a federally designated Comprehensive Cancer Center. Providing advanced training in cancer treatment and research for an international faculty, Dana-Farber conducts ...
The present protocol will compare the biologic effects of PEG-asparaginase vs native-forms of asparaginase in a randomized trial using the same dosages and schedules used in the POG 9411 study. Comprehensive studies, including the measurement of antibodies and asparagine levels as well as the pharmacokinetics of L-asparaginase, will be performed. This protocol will also study the changes in topoisomerase I and topoisomerase II levels and the fractions of topoisomerase I/II translocations in malignant lymphoblasts after upfront window topotecan therapy, and correlate oncolytic response with these changes. Secondary objectives include: - To compare changes in asparagine levels 28 days after initiation of treatment with asparaginase between the two groups. - To estimate the pharmacokinetics of L-asparaginase, compare the pharmacokinetics between the two groups of patients, and correlate the pharmacokinetics with the development of antibody to asparaginase and depletion of asparagine. - To measure ...
BOSTONThe Dana-Farber Cancer Institute and the National Foundation for...With eight other NFCR research centers at universities and research ho...How the Center Works...Traditionally monoclonal antibodies have been derived from mouse mode...,Dana-Farber,launches,NFCR,Center,for,Therapeutic,Antibody,Research,and,Engineering,biological,biology news articles,biology news today,latest biology news,current biology news,biology newsletters
2017 PCF Challenge Award ($1 Million) Principal Investigators: Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Mary-Ellen Taplin, MD (Harvard: Dana-Farber Cancer Institute) Co-Investigators: Wassim Abida, MD, PhD (Memorial Sloan Kettering Cancer Center), Anuradha Gopalan, MD (Memorial Sloan Kettering Cancer Center), Glenn Heller, PhD (Memorial Sloan Kettering Cancer Center), Maika Mitchell, PhD (Memorial Sloan Kettering Cancer Center), Nikolaus Schultz, PhD (Memorial Sloan Kettering Cancer Center), Steven Balk, MD, PhD (Harvard: Beth Israel Deaconess Medical Center), Atish Choudhury, MD, PhD (Harvard: Dana-Farber Cancer Institute), Eliezer Van Allen, MD (Harvard: Dana-Farber Cancer Institute), Adam Kibel, MD (Harvard: Brigham and Womens Hospital), Huihui Ye, MD, MSc (Harvard: Beth Israel Deaconess Medical Center), Rosina Lis, MD (Harvard: Dana-Farber Cancer Institute), Wai Yi Tsui, MD, PhD (Memorial Sloan Kettering Cancer Center), Michaela Bowden, PhD (Harvard: Dana-Farber Cancer ...
l-Asparaginase is a key therapeutic agent for treatment of childhood acute lymphoblastic leukemia (ALL). There is wide individual variation in pharmacokinetics, and little is known about its metabolism. The mechanisms of therapeutic failure with l-asparaginase remain speculative. Here, we now report that 2 lysosomal cysteine proteases present in lymphoblasts are able to degrade l-asparaginase. Cathepsin B (CTSB), which is produced constitutively by normal and leukemic cells, degraded asparaginase produced by Escherichia coli (ASNase) and Erwinia chrysanthemi. Asparaginyl endopeptidase (AEP), which is overexpressed predominantly in high-risk subsets of ALL, specifically degraded ASNase. AEP thereby destroys ASNase activity and may also potentiate antigen processing, leading to allergic reactions. Using AEP-mediated cleavage sequences, we modeled the effects of the protease on ASNase and created a number of recombinant ASNase products. The N24 residue on the flexible active loop was identified as ...
Extranodal NKT cell lymphoma Image NCI. Extranodal natural killerT-cell lymphoma nasal type ENKTL has a long-winded title but is an aggressive form of cancer that is difficult to treat successfully. It tends to affect people in Latin America and Asia rather then the West but is becoming more prevalent in the US. Although it has been described as...
Gordon J. Freeman, PhD Find a cancer doctor with Dana Farbers physician directory. Read how to search for a cancer doctor by name for breast cancer, cervical cancer, ovarian cancer, lung cancer, stomach cancer, testicular cancer, prostate cancer, sarcoma, lymphoma, leukemia, brain tumor, melanoma, bladder cancer, blood disorders, skin cancer, colon cancer, and more at Dana-Farber Cancer Institute.
Dana-Farber Cancer Institute is a top cancer center where leading mesothelioma doctors use the latest mesothelioma treatment protocols to help their cancer patients.
2017 PCF Challenge Award ($1 Million) Award Donor: Janssen Pharmaceuticals Principal Investigators: Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Mary-Ellen Taplin, MD (Harvard: Dana-Farber Cancer Institute) Co-Investigators: Wassim Abida, MD, PhD (Memorial Sloan Kettering Cancer Center), Anuradha Gopalan, MD (Memorial Sloan Kettering Cancer Center), Glenn Heller, PhD (Memorial Sloan Kettering Cancer Center), Maika Mitchell, PhD (Memorial Sloan Kettering Cancer Center), Nikolaus Schultz, PhD (Memorial Sloan Kettering Cancer Center), Steven Balk, MD, PhD (Harvard: Beth Israel Deaconess Medical Center), Atish Choudhury, MD, PhD (Harvard: Dana-Farber Cancer Institute), Eliezer Van Allen, MD (Harvard: Dana-Farber Cancer Institute), Adam Kibel, MD (Harvard: Brigham and Womens Hospital), Huihui Ye, MD, MSc (Harvard: Beth Israel Deaconess Medical Center), Rosina Lis, MD (Harvard: Dana-Farber Cancer Institute), Wai Yi Tsui, MD, PhD (Memorial Sloan Kettering Cancer Center), Michaela Bowden, ...
Although dyslipidemia has been reported during ALL therapy, there have been few systematic studies, and no prior study with dex pharmacokinetics (PK) or asparaginase biomarkers. We studied serum high density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides, and cholesterol in 313 pediatric ALL patients enrolled on St. Jude Total XV at baseline (day 15 consolidation), and weeks (wks) 7, 8 and 12 of continuation therapy. Patients on the standard/high risk (SHR) arm (n=163) were exposed to more asparaginase (wks 1-12) than those on the low risk (LR) arm (n=150, wks 7-9) as reflected by lower serum albumin at wks 7, 8, and 12 (p ,10-6, all time points). Dex was given during wks 1, 4, 7, and 9. Dex PK was assessed at the start and end of wk 7.. LDL decreased after asparaginase (wk 8 in the LR and wk 7 in the SHR arm). HDL decreased from wk 7 to 8, after one wk of dex and asparaginase. Cholesterol increased during therapy. The largest effect of therapy was on triglycerides, which ...
V.3.1 - Rechutes neuro-méningées : extrait du FRALL 90 4 cures à 2 semaines dintervalle sont prévues Methotrexate 8g/m² dose totale scindée en 2g/m² IV en 1 h puis 6g/m² en 23 h Cyclophosphamide 600 mg/m² à débuter dès la fin du metho Rescue acide folinique 4 après la fin du metho PL triple (Cytarabine 40 mg, Methotrexate 15 mg, Depomedrol 40 mg ) 3 fois par semaine jusquà stérilisation du LCR Vincristine 2 mg IVL J1 Methotrexate 80 mg/m² J1 Asparaginase 40 000 UI IV J2 Vincristine 2 mg IVL J8 Methotrexate 120 mg/m² J8 Asparaginase 40 000 UI IV J9 Vincristine 2 mg IVL J15 Methotrexate 160 mg/m² J15 Asparaginase 40 000 UI IV J16 Vincristine 2 mg IVL J22 Methotrexate 200 mg/m² J22 Asparaginase 40 000 UI IV J23 Cyclophosphamide 300 mg/m² IV toutes les 12 h J1 J2 J3 Doxorubicine 50 mg/m² IV J4 Vincristine 2 mg IVL J4 Dexamethasone 40 mg IV J1 à J4 Methotrexate 200 mg/m² en 2 h (IV bolus) puis 800 mg/m² en 22 h IVC à J1 Rescue acide folinique Cytarabine 3 g/m² toutes les ...
Brand Names Elspar Kidrolase (There may be other brand names for this medication) How is Asparaginase Administered? Your medicine may be given by given intravenously (IV), which means it will be given through a tube placed in a vein, usually in your arm, wrist, hand or chest. You may also receive the drug through a shot in a large muscle in your buttock, upper arm or thigh. (IM injection) What is it Used For? This drug is used to treat certain kinds of leukemia and other cancers.
Search for Asparaginase (5000IU) Manufacturers / Generic Brands / Substitute / alternatives, prices, m.r.p. Order Medicines online on PillsBills.com. Free shipping all over India.
Asparaginase is an important drug i the treatment of childhood leukaemia.. The aim of this project is to study the pharmacokinetics, pharmacodynamics and antibody development and hypersensitivity reactions during prolonged PEG-asparaginase treatment.. Study part 1) Asparaginase pharmacokinetics and pharmacodynamics during prolonged PEG-asparaginase treatment: A NOPHO ALL-2008 study. Study part 2) Asparagine depletion in cerebrospinal fluid: A NOPHO ALL-2008 study. Study part 3) A characterization of PEG-asparaginase hypersensitivity in children treated according to the NOPHO ALL 2008 protocol. Perspectives: New knowledge about PEG-asparaginase treatment regarding dosing, dosing interval, adverse effects and EFS, which may lead to improved future therapy. Patients: Children diagnosed with acute lymphoblastic leukaemia in the Nordic Countries ...
Asparaginase is a critical agent in the treatment of ALL. This enzyme deaminates asparagine, interfering with protein synthesis and resulting in cell death as lymphoblasts are deficient in asparagine synthetase. Eryaspase is a dispersion of homologous red blood cells (RBCs) encapsulating L-asparaginase formulated in a preservative solution for infusion. The formulation of eryaspase has evolved during its development. Two sources of L-asparaginase (drug substance) from Medac GmbH can be used as raw material and encapsulated in the RBCs: native (Kidrolase®) or recombinant L-asparaginase (Spectrila®). This study is designed to investigate the PK comparability of both eryaspase formulations: native or recombinant asparaginase as the starting material, when administered as monotherapy and in combination with chemotherapy during induction and consolidation phases for the treatment of children and young adults presenting with ALL/LBL. ...
On study CCG-161 of the Childrens Cancer Study Group (CCSG), 631 children with acute lymphoblastic leukemia (ALL) at low risk for relapse were randomized to receive monthly pulses of vincristine-prednisone (VCR-PDN ) during maintenance therapy in addition to standard therapy with mercaptopurine (6MP) and methotrexate (MTX), and either cranial irradiation during consolidation or intrathecal (IT) MTX every 3 months during maintenance. All patients received six doses of IT MTX during induction and consolidation. With a minimum follow-up time of 4.25 years, 76.7% receiving VCR-PDN were in continuous complete remission at 5 years, in contrast to 63.9% receiving 6MP-MTX alone (P = .002). The difference in relapse-free survival was due primarily to bone marrow relapse (P = .0008), and in boys also to testicular relapse (P = .003). Among the nonirradiated patients, the 5-year disease-free survival (DFS) was 79.4% for patients randomized to the VCR-PDN pulses, in contrast to 61.2% for the patients ...
AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration AbbVie and Harpoon Therapeutics announced that they have entered an immuno-oncology research collaboration. [AbbVie, Inc.] Press Release Dana-Farber Cancer Institute Joins the Parker Institute for Cancer Immunotherapy The Parker Institute for Cancer Immunotherapy announced that researchers at Dana-Farber Cancer Institute have joined its network. Dana-Farber is a leader in cancer research and brings a team of experts who will collaborate with Parker Institute investigators to enhance and expand research projects and clinical trials. [Dana-Farber Cancer Institute] Press Release Kites Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma after Two or More Lines of Systemic Therapy Kite announced that the FDA has granted regular approval to Yescarta™, the first CAR T therapy for the treatment of adult ...
Larcom had heard about Dana-Farber from her brother Austin, who had ridden for years in the Pan-Mass Challenge (PMC). With help from the Army and Dana-Farber, Larcom, four months pregnant, quickly flew to Boston. There she and her unborn baby met David C. Fisher, MD, a specialist in hematologic oncology - blood cancers including non-Hodgkin lymphoma. Fisher had been treating patients with the disease for more than a decade, but this was one of the first pregnant women he had seen.. "Though we did not have extensive data, we did think that the baby could tolerate exposure to chemotherapy after the first trimester," explains Fisher. "Elizabeth bravely accepted the challenge. As stressful as chemotherapy can be, we tried to minimize side effects so as not to risk a premature birth. The nursing staff at Dana-Farber was, as usual, wonderful in helping Elizabeth both medically and psychologically.". "We did our research and knew there were risks, to me and the baby," Larcom adds. "But we had so much ...
November 8, 2012 /Press Release/ -- GNS Healthcare, Inc. (GNS), the leading healthcare data analytics company focused on enabling personalized medicine to improve human health, today announced that it has entered into a collaboration with Dana-Farber Cancer Institute (Dana-Farber) and Mount Sinai School of Medicine (Mount Sinai) to create a data-driven computer model of multiple myeloma, the second most common blood cancer in the U.S. that constitutes approximately one percent of all cancers. Created using GNSs supercomputer-driven REFS™ (Reverse Engineering and Forward Simulation) platform, the models will be used to help researchers discover novel therapies for the disease and to help determine the best existing treatments for patients.. "We have made encouraging progress at Dana-Farber Cancer Institute in using gene profiling, proteomic and signaling studies in tumor cell samples treated with existing and novel medicines to get a better understanding of myeloma pathogenesis and to develop ...
While we were in Florida, I spoke with a friend of mine, who I knew was knowledgeable in this area. I asked her who I should contact if I needed a specialist. She said the only person to see is Dr. Philip Kantoff at Dana-Farber.. When I had another PSA test in April, the level had not changed much. My doctor referred me to a urologist. After the initial consult, he performed a biopsy. A few days later the biopsy results came back, with not very good Gleason scores. By this time I had a better understanding of the Prostate, the tests and some of the procedures. I knew that Gleason scores are the standard measure of prostate cancers aggressiveness.. My urologist suggested immediate surgery, then some radiation follow-up if needed. My wife and I were not comfortable with this course of action because we had not yet seen an oncologist. We made an appointment with Dr. Kantoff, and had the biopsy sent to Dana-Farber, in advance of our appointment.. Our first full day at Dana-Farber was busy. We were ...
Egyptian Pharmaceutical Journal, a publication of Division of Pharmaceutical and Drug Industries Research, National Research Centre, Egypt
ORIGINAL ARTICLES Minerva Pediatrica 2006 December;58(6):513-24. Expressions of discomfort in adolescents. Clinical reflections resulting from an exploratory study of a group of students. La Grutta S., Guarneri M., Nastri L., Schiera G., Lo Baido R., Sarno L., Roccella M.. Abstract PDF. REVIEWS Minerva Pediatrica 2006 December;58(6):525-36. The relationship between perfectionism, eating disorders and athletes. A review. Forsberg S., Lock J.. Abstract PDF. REVIEWS Minerva Pediatrica 2006 December;58(6):537-49. Neonatal invasive candidiasis. Stronati M., Decembrino L.. Abstract PDF. REVIEWS Minerva Pediatrica 2006 December;58(6):551-6. Breast-feeding. The roots. Ben-Nun L.. Abstract PDF. CASE REPORTS Minerva Pediatrica 2006 December;58(6):557-69. Maternal hyperphenylalaninemia syndrome: neuropsychological evaluation of four subjects during childhood and adolescente. Corsello G., Cicero L., Giuffrè M., La Grutta S., Piccione M., Pusateri F., Ciaccio M., Roccella M.. Abstract PDF. CASE REPORTS ...
This study is for patients with recently diagnosed blood cancer, called acute lymphoblastic leukemia (ALL). The standard treatment for this disease consists of many chemotherapy drugs that are given in different combinations in several steps. Each step of treatment is called a cycle. Patients will be treated with the chemotherapy drugs that are routinely used in ALL and which are given in multiple treatment cycles over several months. All the chemotherapy drugs that are used in this study have been approved by the Food and Drug Administration (FDA).. One of the drugs, which is typically given to patients with ALL, is called Asparaginase. It is given together with the other drugs throughout the different cycles of treatment. This drug can be derived from several sources. The standard source is called E. coli Asparaginase, which is associated with a risk of allergic reactions. This drug stays in the body for a very short period of time; therefore, it has to be injected daily for 9-14 days in a ...
Called "beige fat," the cells are found in scattered pea-sized deposits beneath the skin near the collarbone and along the spine in adult humans. Because this type of fat can burn off calories - rather than store them, as "white fat" cells do - beige fat cells might spawn new therapies for obesity and diabetes, according to researchers led by Bruce Spiegelman, PhD, of Dana-Farber.. Spiegelman is the senior author of a report scheduled for advance online publication on July 12 by the journal Cell. The print issue of Cell will publish on July 20.. The study found that beige fat is genetically distinct from "brown fat," which also burns calories to generate heat. Brown fat is found in small mammals and human infants, where it protects against harm from cold. White fat, on the other hand, stores calories, and excess white fat contributes to obesity.. Existence of this third type of fat (in addition to white and brown) had been proposed in a paper by Spiegelmans lab in 2008, but the Dana-Farber team ...
Health,Scientists at the Dana-Farber Cancer Institute have identified a prote... Identification of this HIV-blocking factor opens many new avenues...,HIV,blocking,protein,in,Monkey,,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
103 Ansa jobs. Find your next opportunity on Simply Hired. New jobs are posted every day. Simply Hired makes your Ansa job search easier by showing the newest jobs with salary estimates, company ratings, and more. There are over 103 Ansa positions available
China High Quality L-Asparagine, Find details about China L-Asparagine from High Quality L-Asparagine - Qingdao Sunrise Biotechnology Co., Ltd.
2016 Victoria and Vinny Smith - PCF Challenge Award Principal Investigator: Johann de Bono, MD, PhD (Institute of Cancer Research), Andrew Cato, PhD (Karlsruhe Institute of Technology), Stephen Plymate, MD, PhD (University of Washington), Myles Brown, MD (Dana-Farber Cancer Institute) Co-Investigators: Laura Cato, PhD (Dana-Farber Cancer Institute), Bissan Al-Lazikani, PhD (The Institute of Cancer Research), Adam Sharp, MD, PhD (The Institute of Cancer Research), Paul Workman, PhD, (The Institute of Cancer Research), Julian Blagg, PhD (The Institute of Cancer Research), Rob van Montfort, PhD (The Institute of Cancer Research), Olivia Rossanese, PhD (The Institute of Cancer Research), Cynthia Sprenger, PhD (University of Washington) Project Title: Targeting the Druggable Interaction between the NH2-Terminal Domain of the Androgen Receptor and BAG-1L, a Key Regulator of AR Function Description: ...
Samples. Healthy donor leukopacks were obtained from Dana-Farber Cancer Institute. Normal bone marrow samples were purchased from AllCells. Multiple myeloma patient blood and bone marrow samples were obtained from Dana-Farber Cancer Institute following informed consent approved by the institutional review boards. Patients were classified as multiple myeloma according to standard diagnostic criteria.. Generation of dendritic cells. Dendritic cells were generated from adherent peripheral blood mononuclear cells (PBMC) in the presence of granulocyte-macrophage colony-stimulating factor (1,000 units/mL) and IL-4 (25 ng/mL; both from R&D Systems). On days 5 to 6, the dendritic cells were matured by lipopolysaccharide (100 ng/mL; Sigma-Aldrich) overnight in the presence of 100 ng/mL α-GalCer (KRN7000; Kirin Brewery) and irradiated at 50 Gy immediately before use.. Expansion of iNKT cells. Due to the low frequency of iNKT cells in PBMCs, iNKT cells were first enriched by staining with unconjugated ...
The present invention is concerned with a series of novel monoclonal antibodies directed against CD22, a B lineage-restricted member of the Ig-superfamily which serves as an adhesion receptor expresse
Bioinformatics community open to all people. Strong emphasis on open access to biological information as well as Free and Open Source software.
The Ogino MPE Lab and the Program in MPE Molecular Pathological Epidemiology host the International Molecular Pathological Epidemiology (MPE) Meeting Series. ...
L-Asparaginase (ASNase) is a drug used in treatment of acute lymphoblastic leukemia. In presence of this enzyme the asparagine, an essential amino acid for biosynthesis, is converted to aspartic acid and ammonia. The malignant cells in patients with ASNase sensitive leukemia depend on exogenous supply of asparagine for survival. Administration of ASNase results in rapid reduction of systemic asparagine causing apoptosis of cancer cells. The effect of this enzyme on normal cells is not significant compared to the malignant cells as the normal cells are capable of generating their own source of asparagine through aspartic acid by way of asparagine synthetase.. Despite its effectiveness, the use of ASNase is not without problems. Due to its bacterial origin, namely E. coli and Erwinia carotovora, ASNase causes immunogenic response in patients and requires administration in hospital setting. The problem is compounded by the fact that ASNase has short half-life which in turn necessitates frequent ...
...BOSTON--Researchers at Dana-Farber Cancer Institute have received a $5...Wayne A. Marasco MD PhD of the Department of Cancer Immunology and ...Since the mid 1990s DARPAs Defense Sciences Office has pioneered ad... This grant will support revolutionary advances in rapid response to n...,Dana-Farber,receive,$5.6,million,grant,to,develop,rapid,countermeasures,to,infectious,agents,biological,biology news articles,biology news today,latest biology news,current biology news,biology newsletters
The U.S. Food and Drug Administration (FDA) recently approved the intravenous administration of Erwinaze® (asparaginase Erwinia chrysanthemi). Erwinaze is utilized as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.1 Administration of Erwinaze through an intravenous infusion provides patients with hypersensitivity […]. ...
The findings come amid growing evidence that adolescents and young adults with ALL do better when treated on pediatric rather than adult protocols. "There are a lot of data to show that young adults with ALL treated on pediatric protocols have fewer relapses than similar patients treated on adult leukemia protocols," Relling said. She noted that these results suggest ALL patients in their 20s and 30s might benefit from adding high-dose methotrexate and asparaginase to treatment. Both drugs block proliferation of cancer cells. They are not widely used in adult cancer treatment, in part because increased age is associated with more complications. Pui said Total XV also demonstrated the vast majority of older adolescents can be cured without undergoing a bone marrow transplant. "This lesson should be extended to young adults," he added.. Total XV incorporated several treatment innovations, including greater use of targeted intravenous high-dose methotrexate and asparaginase for older patients. The ...
TY - JOUR. T1 - ASSISTENZA INTENSIVA NELLE MENINGOENCEFALITI IN ETA PEDIATRICA. AU - Tuo, P.. AU - Silvestri, G.. AU - Balzarini, C.. AU - Tumolo, M.. AU - Pallecchi, A. E.. AU - Pessagno, A.. AU - Mantero, E.. AU - Mazzarello, G. F.. AU - Pisano, F.. AU - Fossa, S.. PY - 1992. Y1 - 1992. UR - http://www.scopus.com/inward/record.url?scp=0026621364&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0026621364&partnerID=8YFLogxK. M3 - Articolo. C2 - 1470066. AN - SCOPUS:0026621364. VL - 44. SP - 141. EP - 146. JO - Minerva Pediatrica. JF - Minerva Pediatrica. SN - 0026-4946. IS - 10 SUPPL. 1. ER - ...
TY - JOUR. T1 - Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. AU - Silverman, Lewis B.. AU - Supko, Jeffrey G.. AU - Stevenson, Kristen E.. AU - Woodward, Christina. AU - Vrooman, Lynda M.. AU - Neuberg, Donna S.. AU - Asselin, Barbara L.. AU - Athale, Uma H.. AU - Clavell, Luis. AU - Cole, Peter D.. AU - Kelly, Kara M.. AU - Laverdière, Caroline. AU - Michon, Bruno. AU - Schorin, Marshall. AU - Schwartz, Cindy L.. AU - OBrien, Jane E.. AU - Cohen, Harvey J.. AU - Sallan, Stephen E.. PY - 2010/2/18. Y1 - 2010/2/18. N2 - Over the past several decades, L-asparaginase, an important component of therapy for acute lymphoblastic leukemia (ALL), has typically been administered intramuscularly rather than intravenously in North America because of concerns regarding anaphylaxis.We evaluated the feasibility of giving polyethylene glycosylated (PEG)-asparaginase, the polyethylene glycol conjugate of Escherichia coli ...
Sex abuse survivors name three promising papal contenders, Other dirty dozen cardinals put on blacklist, , English News, Ansa
ANSA.it English: The website of the Agency ANSA. Latest news, photos, videos and insights about: news, politics, economy, regions, world, sport, football, culture and technology
L-ASPARAGINASE (L-ASNase) has been widely used as a therapeutic agent in the treatment of various lymphoblastic leukemia diseases. This study aimed to isolate and purify local bacterial isolates that are capable of producing L-ASNase, so 150 bacterial isolates from the NileRiver where isolated, purified and their ability to produce L-ASNase was assessed. Among these isolates, 32 bacterial isolates showed their ability to produce L-ASNase, so they were selected for further studies. The most active bacterial isolate in the production of L-ASNase was selected, identified as Escherichia coli and named MG27. Enzyme localization was determined in cultures grown under aerobic and anaerobic conditions. E. coli MG27 was found to produce more L-ASNase in anaerobic conditions compared with that produced under aerobic conditions with 128 folds. Finally, in an attempt to determine the optimum conditions for periplasmic L-ASNase production, the influence of several cultural factors was investigated.
TY - JOUR. T1 - Sequential changes in platelet function and coagulation in leukemic children treated with L-asparaginase, prednisone, and vincristine. AU - Pui, C. H.. AU - Jackson, C. W.. AU - Chesney, C.. AU - Lyles, S. A.. AU - Bowman, W. P.. AU - Abromowitch, M.. AU - Simone, J. V.. PY - 1983/1/1. Y1 - 1983/1/1. UR - http://www.scopus.com/inward/record.url?scp=0021014939&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0021014939&partnerID=8YFLogxK. U2 - 10.1200/JCO.1983.1.6.380. DO - 10.1200/JCO.1983.1.6.380. M3 - Article. C2 - 6583320. AN - SCOPUS:0021014939. VL - 1. SP - 380. EP - 385. JO - Journal of Clinical Oncology. JF - Journal of Clinical Oncology. SN - 0732-183X. IS - 6. ER - ...
Oncologia Ospedale Murri Fermo & Hospice Montegranaro ASUR Marche in Italy is an ESMO Designated Centre of Integrated Oncology and Palliative Care
Fondazione Poliambulanza - U.O. Oncologia Medica, in Italy, is an ESMO Designated Centre of Integrated Oncology and Palliative Care.
Resumo: O presente trabalho buscou contribuir com informações sobre a aplicabilidade do diagnóstico por imagem em cães e gatos com neoplasias, especialmente abordando a utilização da ultrassonografia como técnica de estadiamento e diagnóstico em animais com suspeita de câncer. O trabalho foi subdividido em três capítulos independentes. No primeiro capítulo foi apresentada uma breve revisão de literatura sobre a utilização das técnicas mais usuais de diagnóstico por imagem (radiografia simples e ultrassonografia) na oncologia de pequenos animais. O enfoque da revisão foi apresentar de forma aplicada como estas técnicas podem contribuir em todas as etapas da abordagem ao paciente com neoplasia, desde a triagem oncológica até o seguimento clínico após o tratamento. Desta forma, demonstrou-se uma sistemática de tomada de decisões na escolha do melhor método de imagem abordando contribuições e limitações da técnica durante a investigação das principais neoplasias de ...
Cellceutix Novel Anti-Cancer Drug Kevetrin(TM) Receives IRB and SRC Approvals for Clinical Trials at Harvards Dana-Farber Cancer Institute - read this article along with other careers information, tips and advice on BioSpace
When physician-scientist Jay Bradner left the Dana-Farber Cancer Institute last year, he left behind some key scientific work that had already intrigued a
Presentazione della Struttura La Struttura Complessa di Neurochirurgia Pediatrica è lunica dedicata esclusivamente a questa specializzazione in tutto il Meridione dItalia, ed è in grado di offrire una proposta terapeutica completa per tutte le patologie osservate in età pediatrica.
Shop L-asparagine oxygenase ELISA Kit, Recombinant Protein and L-asparagine oxygenase Antibody at MyBioSource. Custom ELISA Kit, Recombinant Protein and Antibody are available.
Boc Sciences offers cas 160416-17-1 2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl-(N2-Fmoc)-L-asparagine tert-butyl ester in bulk,please inquire us to get a quote for 160416-17-1 2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl-(N2-Fmoc)-L-asparagine tert-butyl ester.
Boc Sciences offers cas 154395-64-9 2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl-(N2-Fmoc)-L-Asparagine in bulk,please inquire us to get a quote for 154395-64-9 2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl-(N2-Fmoc)-L-Asparagine.
Dana-Farber Cancer Institute scientists have developed a mathematical model to predict how a patients tumor is likely to behave and which of several possible treatments is most likely to be effective.. Reporting in the journal Cell Reports, researchers combined several types of data from pre- and post-treatment biopsies of breast tumors to obtain a molecular picture of how the cancer evolved as a result of chemotherapy.. "Better understanding of tumor evolution is key to improving the design of cancer therapies and for truly individualized cancer treatment," said Kornelia Polyak, MD, PhD, a breast cancer researcher in the Susan F. Smith Center for Womens Cancers at Dana-Farber. The model was developed by Polyak and Franziska Michor, PhD, a computational biologist at Dana-Farber.. The study analyzed breast cancer samples from 47 patients who underwent pre-operative chemotherapy to shrink the tumor so it could be removed more easily. The biopsy samples, representing the major types of breast ...
Dana-Farber Cancer Institute scientists have successfully disrupted the function of a cancer gene involved in the formation of most human tumors by tampering with the genes "on" switch and growth signals, rather than targeting the gene itself. The results, achieved in multiple myeloma cells, offer a promising strategy for treating not only myeloma but also many other cancer types driven by the gene MYC, the study authors say. Their findings are being published by the journal Cell on its website Sept. 1 and in its Sept. 16 print edition.. "Cancer is a disease of disregulation of growth genes in a cell, and MYC is a master regulator of these genes," says James E. Bradner, MD, of Dana-Farber, one of the studys senior authors. Previous attempts to shut down MYC by inhibiting it directly with drug molecules have been notably unsuccessful. "In this study, our idea was to switch MYC off, interfering with its ability to activate the cell-growth program.". They did so with a small molecule called JQ1, ...
Guildford, UK, 26 February 2007: ReNeuron Group plc today announces that it has entered into a revenue-sharing agreement with the international Ludwig Institute of Cancer Research (LICR) and the Dana-Farber Cancer Institute, Boston, US, concerning newly-patented research conducted by these institutions on certain gene-based somatic cell expansion technology.. ReNeurons entitlement to revenues generated from the commercial exploitation of this technology stems from a pre-existing agreement between ReNeuron and the LICR going back to 1998. The expansion technology developed at the LICR and Dana-Farber concerns the controlled expansion, or conditional immortalisation, of a range of somatic cells using the SV40 Large T Antigen with a gene variant that renders the cell lines genetically stable and therefore suitable for a range of commercial drug discovery applications. The cell expansion technology has been patented in all major territories worldwide, and, together with an earlier patent in which ...
In June, an article in the Boston Globe covered yet another incursion of pseudoscience into a major academic medical center, this time at the Dana-Farber Cancer Institute. Dana-Farber, located just a couple of miles from the library where Im writing this post, has provided world-class care for children and adults with cancer since 1947. Its kind of a big deal. Sidney Farber,.... ...
Eureka Alert reported the results of a striking finding. Dana-Farber Cancer Institute scientists have demonstrated a new strategy for treating autoimmune disease that successfully blocked the development of rheumatoid arthritis in a mouse model. They say it holds promise for improved treatment of arthritis and other autoimmune disorders in people.. The scientists report in the Journal of Clinical Investigation that infusing a highly specific type of cell that regulates immune responses into arthritis-prone mice shut down the cascade of inflammation that damages tissues and joints.. The method worked best when the infusions of CD8+ Treg cells were given at the same time that the animals were injected with a protein that triggered the arthritis-causing autoimmune reaction. "We found we could almost completely inhibit the disease in this setting," said Harvey Cantor, MD, chair of the Department of Cancer Immunology and AIDS at Dana-Farber and the studys senior author.. Too bad we couldnt predict w ...
In a phase I study, Gilead Sciences targeted agent idelalisib (GS-1101) demonstrated potential for treating relapsed or treatment-resistant chronic lymphocytic leukemia (CLL). Half of the 54 patients in the study experienced rapid tumor shrinkage that lasted for 17 months on average.. The drugs activity was particularly noteworthy given that the patients had already been treated with an average of 5 other therapies, noted the studys first author, Jennifer Brown, MD, PhD, an assistant professor of medicine at Dana-Farber Cancer Institute in Boston, MA. Brown presented the findings at a May 15 press conference for the American Society for Clinical Oncologys (ASCO) 2013 Annual Meeting in Chicago, IL, May 31-June 4.. New, more effective treatments are needed for CLL, a B-cell malignancy, because the vast majority of patients will experience a relapse at some point. In addition, about 20% of patients have refractory disease, meaning that they relapse within 6 months of their initial treatment or ...
Credit: Dana-Farber Cancer Institute More than 60 years ago, British physician Denis Parsons Burkitt and his associates achieved one of the signal successes in cancer medicine when they cured children in sub-Saharan Africa with a form of lymphoma by treating them with high doses of the chemotherapy drug cyclophosphamide. Now,…
SAN FRANCISCO-A highly sensitive photon sensor has shown promise as a means of detecting early, subtle responses to neoadjuvant therapy among patients with soft tissue sarcomas, investigators from the Dana-Farber Cancer Institute reported at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO). 1
Dept of Cancer Immunology and Virology, Dana-Farber Cancer Institute. *BLTs are bone marrow/liver/thymus humanized mice. Breakfast will be served, but will be pastries from Flour Bakery rather than bacon/lettuce/tomato sandwiches.. Breakfast with BLTs is a monthly conference typically held the 2nd Thursday of each month at the Ragon Institute. The conference is named after our most commonly used humanized mouse model - the Bone Marrow/Liver/Thymus (BLT) model. All investigators working with or interested in humanized mouse models of HIV infection are welcome to attend.. For more information about the Humanized Mouse Program, or to present at this conference, contact Drs. Andy Tager and Vlad Vrbanac, Directors of the HU CFAR Humanized Mouse Core. Sponsored by The Harvard University CFAR.. ...
Patients with metastatic, HER2-positive breast cancer who received a combination antibody/chemotherapy drug in a phase 3 clinical trial survived longer, on average, than patients receiving other treatments. Researchers from Dana-Farber Cancer Institute reported the findings at the 2015 San Antonio Breast Cancer Symposium. The TH3RESA trial, which enrolled more than 600 participants in the U.S. […]. ...
Before treating certain patients, Daniel J. DeAngelo, MD, JD, of Harvard Medical School and the Dana-Farber Cancer Institute, will council them on the risk of developing neutropenia, which can result in hospitalization or even an intensive care stay.
Multivitamins during and after chemotherapy has no effect on improving the risk of colon cancer or keep a patient from dying, report .researchers at Dana-Farber Cancer Institute.
Bone-marrow Screening Drive paper Overview The bone-marrow screening drive for Turlough Meehan held on November 10, 2007, at Dennis Fire Department headquarters was unprecedented in terms of the number of potential donors who made the commitment to be tested. Elisé Collins, donor center manager at Dana-Farber Cancer Institute, reports that the drives usually draw between…
Scientists at Dana-Farber Cancer Institute and the Broad Institute have found strikingly high levels of a bacterium in colorectal cancers, a sign that it might contribute to the disease and potentially be a key to diagnosing, preventing, and treating it ...
Scientists, including researchers at Dana-Farber Cancer Institute have identified four subtypes of tumors based on shared mutations and other molecular abnormalities, in a massive effort to catalog the molecular causes of stomach cancer.
Harvard researchers at Dana-Farber Cancer Institute (DFCI) have identified a number of cancer genes that endow melanoma tumors with the ability to metastasize, making it possible to predict whether the tumors are likely to spread.
Yoichiro Mitsuishi, MD, PhD, earned the IASLC Lung Cancer Fellowship Award for 2015-2016 and will study under the mentorship of Matthew Meyerson, MD, PhD, at the Dana-Farber Cancer Institute.
In a significant advance in improving the safety of donor stem cell transplants, a major clinical trial led by researchers at Dana-Farber Cancer Institute and Brigham and Womens Hospital has shown that a novel agent can protect against the most common viral infection that patients face after transplantation.
When prostate cancer progresses to a more-dangerous metastatic state, it does so by resurrecting dormant molecular mechanisms that had guided the fetal development of the prostate gland but had been subsequently switched off, say scientists from Dana-Farber Cancer Institute.
Two research groups from Dana-Farber Cancer Institute have independently discovered a genetic mechanism in cancer cells that influences whether they resist or respond to immunotherapy drugs known as checkpoint inhibitors. The scientists say the findings reveal potential new drug targets and might aid efforts to extend the benefits of immunotherapy treatment to more patients and additional types of cancer.
Cancer Registries and Medical Records Rich Data Resources Carol Lowenstein, MBA, CTR Assistant Director Survey and Data Management Core Dana-Farber Cancer Institute Co-Coordinator, Survey & Statistical
The Dana-Farber Cancer Institute researcher is developing cancer therapeutics based on how the physical structure of DNA contributes to the disease.
Researchers at Dana-Farber Cancer Institute have identified a molecular interaction that triggers a particularly aggressive form of breast cancer, and suggest that attacking this target with selective drugs might improve treatment.
Christopher J. Recklitis, PhD, MPH, of Dana-Farber Cancer Institute, summarizes two key papers on mental health: suicide risk among survivors of head and neck cancer vs other types of cancer; and the .... ...
In article ,3oe33u$s7b at cisunix1.dfci.harvard.edu,, Ian A. York ,york at mbcrr.dfci.harvard.edu, wrote: ,Hidden in the old boxes in our lab in a plasmid called pKONeo. Legend ,has it that its very good at making stable G418-resistant lines; but ,nobody here now knows what it is. In fact nobody here now has ever used ,it, as far as I can tell. Trying Genbank and vector databases didnt ,turn up anything. , ,Anyone know what it is? Who makes/made it? Whether it actually is any ,good at making G418-resistant colonies? Well I have no idea what this plasmid might be but KO is suggestive of some sort of knockout vector. Anyone in your group ever made a knockout mouse? Max , ,Ian ,-- ,Ian York (york at mbcrr.harvard.edu) ,Dana-Farber Cancer Institute, 44 Binney St., Boston MA 02115 ,Phone (617)-632-3921 Fax (617)-632-2627 , ...
The Stanley J. Korsmeyer Memorial Symposium: Targeting Cell Death Pathways for Cancer Therapy Chairperson: Anthony G. Letai, Dana-Farber Cancer Institute, Boston, MA ...
A research duo from Dartmouth and Dana-Farber Cancer Institute has discovered that cancer medications have names that are associated with lightness, small
Harvard scientists at Dana-Farber Cancer Institute say they have for the first time partially reversed age-related degeneration in mice, resulting in new growth of the brain and testes, improved fertility, and the return of a lost cognitive function.
Harvard scientists at Dana-Farber Cancer Institute say they have for the first time partially reversed age-related degeneration in mice, resulting in new g
Researchers at the Dana-Farber Cancer Institute in Boston surveyed more than 2,000 students and staff at 62 U.S. medical schools to assess the availability and quality of instruction in end-of-life care.
TY - JOUR. T1 - La determinazione del GH plasmatico in età pediatrica. AU - Colombo, A.. AU - Forenza, N.. AU - Larizza, D.. AU - Belloni, C.. PY - 1975/12/31. Y1 - 1975/12/31. UR - http://www.scopus.com/inward/record.url?scp=0016866290&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0016866290&partnerID=8YFLogxK. M3 - Articolo. C2 - 1228648. AN - SCOPUS:0016866290. VL - 83. SP - 627. EP - 682. JO - La Pediatria. JF - La Pediatria. SN - 0031-3890. IS - 4. ER - ...
Enquire before purchasing this report -https://www.researchreportsworld.com/enquiry/pre-order-enquiry/15504993. This Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data.. Besides, the report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries client information, which is important for the manufacturers.. What the Medical Asparaginase Market Report Contains:. - Organization profiles of the main rivals alongside their strategic activities and market shares.. - Assurance and examination of the macro and microeconomic variables that influence the Global ...
Wholesale Trader of Amino Acids - L-Asparagine Monohydrate, L-Aspartic Acid, L-Histidine Mono HCL and L-Methionine offered by Delta Chemsol, Mumbai, Maharashtra.
Creative Peptides offers L-Iso-0103, L-ASPARAGINE:H2O (1,4-13C2; ALPHA-15N, 98%) for your research. Find all specific details here.
Product Number , 75190706. CAS Number , 5794-24-1. EC , 218-163-3. Molecular Formula , C4H8N2O3Ï H2O. Molecular Weight , 150.14. Storage Temp , +20°C. Harmonized Tariff code , 29241900900. Signal Word , ...
Cercetatorii au descoperit ca celulele stem ale cancerului de san sunt celule derivate din maduva osoasa. Aceste celule sunt atrase spre cancer si creaza o nisa prin care cancerul respectiv se poate dezvolta si raspandi. Blocand acea nisa se blocheaza metastazarea si dezvoltarea tumorii ...
Dipartimento di Oncologia ed Emato-oncologia, Università degli Studi di Milano and IEO, Istituto Europeo di Oncologia, Milano, Italy
Probabil ca multa lume a auzit de acest medicament de la mass-media ca fiind un medicament minune. Adevarul e ca este o minune a ...
Investigador principal Joan Figueras Felip Investigador post-doctorals MªJosé Ferri Iglesias Rosa Peracaula Investigador pre-doctorals Julia Gil Garcia Helena Salvador Roses
Flammulina velutipes creates asparaginase. Plinabulin is a fungal isolate derivative currently being researched for anticancer ...
... produces L-asparaginase. Sirisha, B.; Haritha, R.; Mohan, Y.S.Y.V. Jagan; Swathi, A.; Ramana, T. (1 ... "Molecular Characterization of Marine Streptomyces enissocaesilis Capable of L-asparaginase Production". Bacteriology Journal. 4 ... January 2014). "Molecular Characterization of Marine Streptomyces enissocaesilis Capable of L-asparaginase Production". ...
L-asparaginase is an enzyme that in humans is encoded by the ASRGL1 gene. The ASRGL1 protein consists of 308 amino acids and is ... The ASRGL1 enzyme has both L-asparaginase and beta-aspartyl peptidase activity and may be involved in the production of L- ... Bush LA, Herr JC, Wolkowicz M, Sherman NE, Shore A, Flickinger CJ (2002). "A novel asparaginase-like protein is a sperm ... ASRGL1 asparaginase like 1". Li, Wenzong; Cantor, Jason R.; Yogesha, S. D.; Yang, Shirley; Chantranupong, Lynne; Liu, June ...
Jerebzoff-Quintin, Simonne; Jerebzoff, Stephan (1985). "L-Asparaginase activity in Leptosphaeria michotii. Isolation and ... "Crystal Structure and Allosteric Regulation of the Cytoplasmic Escherichia coli l-Asparaginase I". Journal of Molecular Biology ...
Lanvers-Kaminsky, Claudia (2017-03-01). "Asparaginase pharmacology: challenges still to be faced". Cancer Chemotherapy and ...
... is hydrolyzed to aspartate by asparaginase. Aspartate then undergoes transamination to form glutamate and ...
It is a form of L-asparaginase which has undergone PEGylation. The drug is manufactured by Exelead, Inc. It is used in the ... Patel SS, Benfield P (Jun 1996). "New drug profile: pegaspargase (Polyethylene Glycol L-Asparaginase)". Clinical ...
As a result, L-asparaginase is a common chemotherapy drug utilized in the treatment of ALL and may have applications in other ... For example, in mouse models, 24 hours after exposure to L-asparaginase, tumors resistant to the depletion responded with 5- to ... However, the opposite effect is visible in cases of asparaginase resistant cancers. In these resistant cancers, the effect of ... It has been further demonstrated in mouse model systems that repeated subculturing of L-asparaginase sensitive tumor cells in ...
Shrivastava A, Khan AA, Shrivastav A, Jain SK, Singhal PK (2012). "Kinetic studies of L-asparaginase from Penicillium digitatum ... Penicillium is a potential source of the leukemia medicine asparaginase. Some countries have approved Beta-glucan fungal ...
For children with low-risk ALL, standard therapy usually consists of three drugs (prednisone, L-asparaginase, and vincristine) ... other drug plans may include L-asparaginase or cyclophosphamide. ...
Asparaginase containing regimens have been used in advanced stage disease. Cutaneous T-cell lymphoma Subcutaneous T-cell ...
"Selective apoptosis of natural killer-cell tumours by l-asparaginase". British Journal of Haematology. 130 (6): 860-868. doi: ...
Bacillus is utilized in the production of the chemotherapy medicine L-asparaginase. Bacillus subtilis is utilized in the ... a bacterium used to produce the chemotherapy medicine asparaginase Fungal isolates Medicinal molds Sponge isolates Streptomyces ...
asparaginase (better tolerance in pediatric patients). *daunorubicin (used in Adult ALL). Central nervous system prophylaxis ...
Kavitha, A; Vijayalakshmi, M (2009). "Optimization and purification of L-asparaginase produced by Streptomyces tendae TK-VL_333 ...
The most common treatment is a combination of cyclophosphamide, vincristine, prednisone, L-asparaginase, and doxorubicin. Other ...
1994). "Hyperglycemia, ketoacidosis and other complications of L-asparaginase in children with acute lymphoblastic leukemia". J ... L-asparaginase, and some antipsychotic agents. The acute administration of stimulants such as amphetamine typically produces ...
6-diazo-5-oxo-L-norleucine and azaserine as affinity inhibitors of glutamin(asparagin)ase.. ...
SurEstructural domain has a similar topology to the N-terminal protein domain of the glutaminase/asparaginase family. The C- ...
N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase is an enzyme that in humans is encoded by the AGA gene. Aspartylglucosaminidase ...
Scientists speculate that these cells along with asparaginase may be what gives the guinea pig cancer resistant properties ( ...
It is also used to induce remission in ALL with dexamethasone and L-Asparaginase, and in combination with prednisone to treat ...
"Optimization of Culture Conditions for Production of the Anti-Leukemic Glutaminase Free L-Asparaginase by Newly Isolated NEAE- ...
Ortlund E, Lacount MW, Lewinski K, Lebioda L (February 2000). "Reactions of Pseudomonas 7A glutaminase-asparaginase with diazo ...
... and fraE a L-asparaginase. Fructose-asparagine is a aminodeoxysugar. It takes the form of a pale yellow solid. It decomposes ...
Asparaginase Erwinia chrysanthemi: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before taking asparaginase Erwinia chrysanthemi,. *tell your doctor and pharmacist if you are allergic to asparaginase Erwinia ... asparaginase [Elspar] or pegaspargase [Oncaspar]). Asparaginase Erwinia chrysanthemi is an enzyme that interferes with natural ... Asparaginase Erwinia chrysanthemi comes as a powder to be added to fluid and injected into a muscle by a doctor or nurse in a ...
Crasnitin has been discontinued.) Spectrila is a new recombinant E. coli asparaginase. Asparaginase produced by Erwinia ... but rather the enzyme asparaginase. After researchers comparing different kinds of asparaginases, the one derived from ... Asparaginase is an enzyme that is used as a medication and in food manufacturing. As a medication it is used to treat acute ... Asparaginase was approved for medical use in the United States in 1978. It is on the World Health Organizations List of ...
Make research projects and school reports about Asparaginase easy with credible articles from our FREE, online encyclopedia and ... Asparaginase Gale Encyclopedia of Cancer COPYRIGHT 2002 The Gale Group Inc.. Asparaginase. Definition. Asparaginase (also known ... Asparaginase is an enzyme made from the bacteria escherichia coli (E. coli). In this country, two forms of asparaginase are ... coli asparaginase. Asparaginase kills cancer cells by depleting a certain protein in the blood (L-asparagine) that is necessary ...
Type I (cytosolic) L-asparaginase (IPR041725). Short name: L-asparaginase_I Overlapping homologous superfamilies *Asparaginase/ ... Asparaginase/glutaminase-like (IPR006034) *Type I L-asparaginase family (IPR006033) *Type I (cytosolic) L-asparaginase ( ... Many bacterial L-asparaginases have both L-asparagine and L-glutamine hydrolysis activities, to a different degree, and some of ... Asparaginases (amidohydrolases, EC:3.5.1.1) are enzymes that catalyze the hydrolysis of asparagine to aspartic acid and ammonia ...
In enzymology, a glutamin-(asparagin-)ase (EC 3.5.1.38) is an enzyme that catalyzes the chemical reaction L-glutamine + H2O ... and properties of Achromobacteraceae glutaminase-asparaginase with antitumor activity". J. Biol. Chem. 247 (1): 84-90. PMID ...
Administration of either Escherichia coli asparaginase or guinea pig serum to C3H/HE mice with the 6C3HED lymphosarcoma is ... This decrease in cellular glycine concentration does not occur in a tumor resistant to asparaginase. The inhibition of the ... lymphosarcoma by asparaginase can be reversed by intraperitoneal injection of asparagine or glycine. This reversal appears to ...
Asparaginase (Erwinia chrysanthemi) reference guide for safe and effective use from the American Society of Health-System ... Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer ... L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011; 117:238-49. [PubMed ... Cautions for Asparaginase (Erwinia chrysanthemi). Contraindications. * History of serious thrombosis with prior asparaginase ...
PEG-L-asparaginase (Pegaspargase) chemotherapy side effects, how its given, how it works, precautions and self care tips for ... The enzyme asparaginase breaks down asparagine in the body. Since the cancer cells cannot make more asparagine, they die. ... Pegaspargase is a modified version of the enzyme asparaginase. When pegaspargase breaks down asparagine it is broken down into ... You will be checked regularly by your doctor while you are taking asparaginase, to monitor side effects and check your response ...
Find user ratings and reviews for asparaginase injection on WebMD including side effects and drug interactions, medication ... Read user comments about the side effects, benefits, and effectiveness of asparaginase injection. ...
N4-(beta-N-acetylglucosaminyl)-L-asparaginase at the US National Library of Medicine Medical Subject Headings (MeSH) Molecular ... N4-(beta-N-acetylglucosaminyl)-L-asparaginase (EC 3.5.1.26, aspartylglucosylamine deaspartylase, aspartylglucosylaminase, ...
Measure asparaginase activity in lysates from yeast or bacteria in only 40 minutes. ... Metabolization of asparaginase prevents acrylamide formation in fried foods (Maillard reaction).. Other asparaginases are used ... direct and automation-ready procedure for measuring asparaginase activity in biological samples. In the assay, Asparaginase ... Asparaginase does not occur naturally in humans but is found in bacteria, plants and many animals (e.g. guinea pigs).. ...
These findings suggest that asparaginase II is produced by E. coli A-l in response to low concentrations of ammonia and that ... It is suggested that E. coli A-l produced L-asparaginase in order to obtain ammonia for the synthesis of glutamine from ... The addition of glucose to the same medium before asparaginase II activity was detected resulted in the production of acid by E ... Glucose was exhausted two hours before ammonia and three hours before asparaginase II activity was detected. The concentration ...
Common brand names: Elspar Summary of Interactions with Vitamins, Herbs, & Foods What Are Nutrient Interactions Types of interactions: Beneficial Adverse Check Replenish Depleted Nutrients Magnesium and Potassium The chemotherapy drug cisplatin may cause excessive loss of magnesium and potassium in the urine...
In this study, a different form of Asparaginase will be used, called PEG-Asparaginase (also called Oncospar), which remains in ... In children there is some early information that PEG-Asparaginase produces fewer antibodies than E.coli Asparaginase. Therefore ... PEG-Asparaginase has recently been approved by the FDA to treat ALL. Most of the experience with the drug has been in children ... Intensified Post Remission Therapy Containing PEG-Asparaginase. The safety and scientific validity of this study is the ...
Browse our L-Asparaginase Antibodies all backed by our Guarantee+. ... anti-L asparaginase 1 antibody, anti-L asparaginase 2 antibody, anti-L asparaginase I antibody, anti-L asparaginase II antibody ... anti-L-Asparaginase antibody, anti-ansB antibody, anti-AnsA antibody, anti-Asparaginase antibody, anti-Colaspase antibody, anti ... L-Asparaginase Antibodies. We offer L-Asparaginase Antibodies for use in common research applications: ELISA, ...
Asparaginase Erwinia chrysanthemi is used to treat acute lymphocytic lymphoma. Asparaginase Erwinia chrysanthemi may also be ... Asparaginase is a cancer medication that interferes with the growth and spread of cancer cells in the body. ... What is asparaginase Erwinia chrysanthemi?. Asparaginase is a cancer medication that interferes with the growth and spread of ... Asparaginase Erwinia chrysanthemi is used to treat acute lymphocytic lymphoma.. You should not receive asparaginase Erwinia ...
N(4)-(Beta-N-acetylglucosaminyl)-L-asparaginase (EC:3.5.1.26*Search proteins in UniProtKB for this EC number. ... sp,Q47898,ASPG_ELIMR N(4)-(Beta-N-acetylglucosaminyl)-L-asparaginase OS=Elizabethkingia miricola OX=172045 PE=1 SV=1 ...
AsparaginaseImported. ,p>Information which has been imported from another database using automatic procedures.,/p> ,p>,a href ... tr,M1IN77,M1IN77_9CREN Asparaginase OS=Sulfolobus acidocaldarius N8 OX=1028566 GN=SacN8_01980 PE=4 SV=1 ...
Interestingly, E289 belongs to a loop that is very variable in L-asparaginases from the structure, sequence and length point of ... In contrast to other known L-asparaginases, Helicobacter pylori CCUG 17874 type II enzyme (HpASNase) is cooperative and has a ... Bacterial asparaginases (amidohydrolases, EC 3.5.1.1) are important enzymes in cancer therapy, especially for Acute ... In contrast to other known L-asparaginases, Helicobacter pylori CCUG 17874 type II enzyme (HpASNase) is cooperative and has a ...
l-Asparaginase is a key therapeutic agent for treatment of childhood acute lymphoblastic leukemia (ALL). There is wide ... Here, we now report that 2 lysosomal cysteine proteases present in lymphoblasts are able to degrade l-asparaginase. Cathepsin B ... The mechanisms of therapeutic failure with l-asparaginase remain speculative. ... CTSB), which is produced constitutively by normal and leukemic cells, degraded asparaginase produced by Escherichia coli ( ...
Downloading a figure as powerpoint requires a browser with javascript support. Enable javascript and try again For help please contact [email protected] ...
Biochemical and Pharmacological Studies with Asparaginase in Man. Takao Ohnuma, James F. Holland, Arnold Freeman and Lucius F. ... Biochemical and Pharmacological Studies with Asparaginase in Man. Takao Ohnuma, James F. Holland, Arnold Freeman and Lucius F. ... Biochemical and Pharmacological Studies with Asparaginase in Man. Takao Ohnuma, James F. Holland, Arnold Freeman and Lucius F. ... Biochemical and Pharmacological Studies with Asparaginase in Man Message Subject (Your Name) has forwarded a page to you from ...
Copyright 2020 © Index-China Medicine shares knowledge about good medicine and remedies. Website is in testing process, content is for reference only. All information about drug use should be consulted with a qualified physician. ...
The PDB archive contains information about experimentally-determined structures of proteins, nucleic acids, and complex assemblies. As a member of the wwPDB, the RCSB PDB curates and annotates PDB data according to agreed upon standards. The RCSB PDB also provides a variety of tools and resources. Users can perform simple and advanced searches based on annotations relating to sequence, structure and function. These molecules are visualized, downloaded, and analyzed by users who range from students to specialized scientists.
The L-asparaginase (ASNase) obtained from yeasts species has been poorly studied and a new yeast ASNase could be an alternative ... A L-asparaginase (ASNase) obtida a partir de espécies de leveduras tem sido pouco estudada e uma nova ASNase de levedura pode ... The L-asparaginase (ASNase) obtained from yeasts species has been poorly studied and a new yeast ASNase could be an alternative ... Produção de L-asparaginase de interesse farmacêutico a partir de leveduras isoladas do continente Antártico ...
  • Asparaginase is used as part of an induction regimen for the treatment of acute lymphocytic leukemia (ALL) in children. (encyclopedia.com)
  • Other asparaginases are used to treat acute lymphoblastic leukemia (ALL) and some other hematopoietic neoplasms (e.g. multiple myeloma). (abcam.com)
  • Treatment Of Newly Diagnosed Adult Acute Lymphoblastic Leukemia With Intensified Post Remission Therapy Containing PEG-Asparaginase. (clinicaltrials.gov)
  • Asparaginase Erwinia chrysanthemi is used to treat acute lymphocytic lymphoma. (adventisthealthcare.com)
  • Bacterial asparaginases (amidohydrolases, EC 3.5.1.1) are important enzymes in cancer therapy, especially for Acute Lymphoblastic Leukemia. (mdpi.com)
  • l-Asparaginase is a key therapeutic agent for treatment of childhood acute lymphoblastic leukemia (ALL). (jci.org)
  • L-ASPARAGINASE (L- a SPARE a gi nase) is used to treat acute lymphocytic leukemia (ALL). (ahealthyme.com)
  • L-asparaginase (L-ASNase) is FDA approved enzyme which is widely used in pharmacy for treatment of acute lymphoblastic leukemia. (ukessays.com)
  • The L-asparaginase enzyme is an important factor in chemotherapy that is used for acute lymphoblastic leukemia (ALL) [7, (ukessays.com)
  • L-asparaginase derived from Escherichia coli has been used in the treatment of acute leukemia since 1960. (ukessays.com)
  • Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. (springer.com)
  • Data from clinical trials suggest that polyethylene glycol‑conjugated asparaginase (PEG asparaginase) should be recommended as a replacement for Escherichia coli (E. coli) asparaginase in the treatment of pediatric acute lymphoblastic leukemia (ALL) due to its prolonged effect, similar safety profile and convenience. (spandidos-publications.com)
  • Asparaginase is one of the major anticancer drugs used in the treatment of acute lymphoblastic leukemia (ALL) ( 1 , 2 ). (spandidos-publications.com)
  • L-Asparaginase has significantly improved outcome for children with acute lymphoblastic leukemia and has become an essential component of multiagent chemotherapy. (ovid.com)
  • However, there are many adverse events due to L-asparaginase, including acute pancreatitis. (ovid.com)
  • Asparaginase is an essential component of pediatric acute lymphoblastic leukemia (ALL) therapy. (springermedizin.de)
  • Raetz EA, Salzer WL (2010) Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. (springermedizin.de)
  • Woo MH, Hak LJ, Storm MC, Evans WE, Sandlund JT, Rivera GK, Wang B, Pui CH, Relling MV (1998) Anti-asparaginase antibodies following E . coli asparaginase therapy in pediatric acute lymphoblastic leukemia. (springermedizin.de)
  • Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines. (cnrs.fr)
  • Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors. (semanticscholar.org)
  • l -asparaginase (L-ase) is a major drug used to treat acute lymphoblastic leukemia (ALL) . (semanticscholar.org)
  • asparaginase (as-PAYR-uh-jih-NAYS) is a drug that is used to treat acute lymphoblastic leukemia (ALL) and is being studied in the treatment of some other types of cancer . (wikimd.org)
  • Asparaginase is a bacterial enzyme that is used as an antineoplastic agent, largely in the therapy of acute lymphocytic leukemia . (wikimd.org)
  • Asparaginase, prepared from E. coli, was introduced into cancer chemotherapy over 50 years ago and remains an important agent in the therapy of acute lymphocytic leukemia . (wikimd.org)
  • Outcomes Following Discontinuation of E. coli l-Asparaginase Upon Severe Allergic Reactions in Children With Acute Lymphoblastic Leukemia. (semanticscholar.org)
  • Safety profile of Erwinia asparaginase treatment in adults with newly diagnosed acute lymphoblastic leukemia: a retrospective monocenter study. (semanticscholar.org)
  • Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. (semanticscholar.org)
  • Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. (semanticscholar.org)
  • In two patients with advanced acute lymphatic leukemia, the therapy with the enzyme L-asparaginase improved their conditions significantly. (jkzx.com)
  • 11/18/2011: Initial FDA approval "as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase . (hemonc.org)
  • Asparaginase is an important chemotherapeutic agent used in the treatment of haematological malignancies such as acute lymphoblastic leukemia. (oatext.com)
  • In this case series, six paediatric patients with acute leukaemia are presented and management issues in relation to diagnostic challenge and surgical intervention for asparaginase-associated pancreatitis are discussed. (oatext.com)
  • Asparaginase is an enzyme that has been used in treatment regimens for childhood acute lymphoblastic leukemia (ALL) since 1961 . (oatext.com)
  • The occurrence of venous thromboembolism (VTE) in acute lymphocytic leukemia patients receiving L-asparaginase therapy may cause significant morbidity, neurological sequela and possibly worse outcomes. (nebraska.edu)
  • Goyal, G & Bhatt, VR 2015, ' L-asparaginase and venous thromboembolism in acute lymphocytic leukemia ', Future Oncology , vol. 11, no. 17, pp. 2459-2470. (nebraska.edu)
  • Over the past several decades, L-asparaginase, an important component of therapy for acute lymphoblastic leukemia (ALL), has typically been administered intramuscularly rather than intravenously in North America because of concerns regarding anaphylaxis.We evaluated the feasibility of giving polyethylene glycosylated (PEG)-asparaginase, the polyethylene glycol conjugate of Escherichia coli L-asparaginase, by intravenous infusion in children with ALL. (elsevier.com)
  • Erwinaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase. (news-medical.net)
  • Primary Examiner-Lionel M. Shapiro Attorney-Craig, Antonelli and Hill ABSTRACT: The antitumor activity of L-asparaginase produced from the cultured cells of micro-organisms belonging to the genus Serratia is retained by a purification process wherein, as one of the steps in the purification procedure, the enzymatic liquid is heated to a temperature of at least 60C. (google.com)
  • Site-directed mutagenesis of Rhodospirillum rubrum l -asparaginase (RrA) was performed in order to identify sites of the protein molecule important for its therapeutic and physico-chemical properties. (springer.com)
  • So, higher levels of this protein indicate a poor response to asparaginase treatment. (separationsnow.com)
  • Decreased AT and fibrinogen levels resulting from the strong suppression of protein synthesis by L-asparaginase were predictive signs for AAP. (ovid.com)
  • L-asparaginase has many side effects , one of which is hepatic injury that is characterized by inhibition of hepatic protein synthesis and steatosis, which can be severe and lead to death from hepatic failure. (wikimd.org)
  • The human asparaginase-like protein 1 hASRGL1 is an Ntn hydrolase with beta-aspartyl peptidase activity. (nih.gov)
  • Cell growth stimulation by CRASH, an asparaginase-like protein overexpressed in human tumors and metastatic breast cancers. (nih.gov)
  • A cDNA sequence encoding the sequence of L-Asparaginase was constructred and used to recombinantly synthesize the protein. (enquirebio.com)
  • SurEstructural domain has a similar topology to the N-terminal protein domain of the glutaminase/asparaginase family. (wikipedia.org)
  • Administration of either Escherichia coli asparaginase or guinea pig serum to C3H/HE mice with the 6C3HED lymphosarcoma is followed by depression of glycine in the tumor. (sciencemag.org)
  • This decrease in cellular glycine concentration does not occur in a tumor resistant to asparaginase. (sciencemag.org)
  • L-asparaginase is an anti-tumor agent derived from E.coli. (biovendor.com)
  • Treatment of the 1-day-old Ehrlich ascites tumor with combinations of selected doses of l -asparaginase and the l -glutamine antagonist, 6-diazo-5-oxo- l -norleucine, or of the l -glutamine acid antagonist, dl -methionine- dl -sulfoximine, produced significantly more growth inhibition without a marked increase in host toxicity than did treatment with l -asparaginase administered alone. (aacrjournals.org)
  • In the 3-day-old tumor treated with the combination of l -asparaginase and 6-diazo-5-oxo- l -norleucine, there was a significant enhancement of growth inhibition as compared with the effect of either drug used alone. (aacrjournals.org)
  • Combinations of l -asparaginase and 6-diazo-5-oxo- l -norleucine produced increased antitumor effects in mouse melanoma B16 and to a lesser degree in the solid form of Ehrlich tumor and Walker carcinosarcoma 256 of the rat. (aacrjournals.org)
  • Enhanced antitumor activity was seen when 2-deoxy- d -glucose was included with l -asparaginase, azaserine, dl -methionine- dl -sulfoximine, and their combinations in treatment of the Ehrlich ascites tumor. (aacrjournals.org)
  • Schalk AM, Nguyen HA, Rigouin C, Lavie A. Identification and structural analysis of an L-asparaginase enzyme from guinea pig with putative tumor cell killing properties. (kerafast.com)
  • Long-lived immunity to this tumor in A/IISc Wistar rats following treatment of tumor bearing animals with M. tuberculosis H 37 R a , pH 9.6 l-asparaginase has been observed. (elsevier.com)
  • Lymphatic tumor cells require huge amount of L-asparaginase for malignant growth. (com.ng)
  • Ever since, L-asparaginase anti-tumor activity was first demonstrated, its production using microbial systems has attracted considerable attention owing to their cost effective and eco-friendly nature. (com.ng)
  • Cathepsin B (CTSB), which is produced constitutively by normal and leukemic cells, degraded asparaginase produced by Escherichia coli (ASNase) and Erwinia chrysanthemi. (jci.org)
  • The L-asparaginase (ASNase) obtained from yeasts species has been poorly studied and a new yeast ASNase could be an alternative to minimize the side effect in the treatment of lymphoblastic leukemia. (usp.br)
  • A L-asparaginase (ASNase) obtida a partir de espécies de leveduras tem sido pouco estudada e uma nova ASNase de levedura pode ser uma alternativa para minimizar os efeitos adversos no tratamento da leucemia linfoblástica. (usp.br)
  • Prolonged use of the enzyme from a single source can lead to hypersensitive reactions and hence there is a continual need in isolating asparaginase from various microorganisms with lesser toxicity and side effects. (rjptonline.org)
  • To test if intramuscular PEG-asparaginase administered either at six or two week intervals from day 92 until 8 months from diagnosis for patients with non-HR ALL will result in equal probability of EFS. (knowcancer.com)
  • Baskar G, Rajasekar V, Renganathan S (2011) Modeling and optimization of L-asparaginase production by Enterobacter aerogenes using artificial neural network linked genetic algorithm. (springer.com)
  • 2016). 'Production and optimization of L-asparaginase in Escherichia coli ', Egyptian Journal of Botany , 56(1), pp. 203-224. (ekb.eg)
  • The results revealed that PEG asparaginase had a comparable complete remission rate (95.65 vs. 90.79%), median overall survival time (14.07 vs. 16.29 months) and median relapse‑free survival time (10.00 vs. 8.57 months) with E. coli asparaginase. (spandidos-publications.com)
  • As E. coli asparaginase was administered to the patient in the lower dosage regimen of PEG asparaginase, she was undertreated, but at the end of the treatment the patient was in complete remission. (ru.nl)
  • It is also used to induce remission in ALL with dexamethasone and L-Asparaginase, and in combination with prednisone to treat childhood leukemia. (wikipedia.org)
  • Between 2005 and 2007, 197 patients (age, 1-17 years) were enrolled on Dana-Farber Cancer Institute ALL Consortium Protocol 05-01 and received a single dose of intravenous PEG-asparaginase (2500 IU/m2) over 1 hour during emission induction. (elsevier.com)
  • Nevertheless, the number of isolates with L-asparaginase production differs among plants. (springer.com)
  • A. paniculata has the most number of endophytes with L-asparaginase activities (39 of the 50 isolates), compared to P. bleo , O. diffusa , C. citratus , and M. koenigii with 15, 7, 2, and 1 positive isolate(s), respectively. (springer.com)
  • L-Asparaginase Activity in Cell Lysates and Culture Media of Halophilic Bacterial Isolates', Iranian Journal of Pharmaceutical Research , 15(3), pp. 435-440. (ac.ir)
  • None of the isolates appeared to produce appreciable amounts of extracellular L-asparaginase. (ac.ir)
  • Among the isolates that produced intracellular L-asparaginase, 5 moderate and 1 extreme halophiles were selected for further study based on their observed activity level. (ac.ir)
  • ALP03 was among the active isolates exhibited the highest enzyme activity of L-asparaginase and showed a maximum 97.93 % similarity of its 16S rRNA gene sequence to Streptomyces spongiae Sp080513SC-24T. (microbiologyresearch.org)
  • Used in some patients who have had a hypersensitivity reaction to another form of asparaginase. (chemocare.com)
  • In this study, a different form of Asparaginase will be used, called PEG-Asparaginase (also called Oncospar), which remains in the body for about two weeks, therefore, it can be given only once in a cycle of treatment and still maintains high blood levels of the drug. (clinicaltrials.gov)
  • In children it was found to be as safe as the standard form of Asparaginase and with less allergic reaction. (clinicaltrials.gov)
  • The present study was intended to isolate actinomycetes VSM-6 from deep sea sediment samples of Bay of Bengal that is potent to produce L - asparaginase. (phcogj.com)
  • 2003) has been known to produce L-asparaginase. (com.ng)
  • N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase is an enzyme that in humans is encoded by the AGA gene. (wikipedia.org)
  • These findings suggest that asparaginase II is produced by E. coli A-l in response to low concentrations of ammonia and that exogenously supplied nitrogen compounds may play a major role in the regulation of this enzyme. (unt.edu)
  • Furthermore, these data suggest that asparaginase had a larger effect than dex on these changes and that the largest changes were in serum triglycerides. (aacrjournals.org)
  • Determined is the structure of the first mammalian plant-type asparaginase in both a precursor and fully activated form. (nih.gov)
  • Asparaginase Erwinia chrysanthemi is an enzyme that interferes with natural substances necessary for cancer cell growth. (medlineplus.gov)
  • The discovery and development of asparaginase as an anti-cancer drug began in 1953, when scientists first observed that lymphomas in rat and mice regressed after treatment with guinea pig serum. (wikipedia.org)
  • Asparaginase is a cancer medication that interferes with the growth and spread of cancer cells in the body. (adventisthealthcare.com)
  • They can be developed for upscale production under optimized conditions, to produce sufficient L-asparaginase for cancer treatment. (springer.com)
  • The cytotoxicity assays against diverse types of cancer cell lines will be carried out to assess the anticancer potential of isolate ALP03 and the others showing distinct L-asparaginase activity. (microbiologyresearch.org)
  • Asparaginase has activity against other cancer types, but is rarely used for other indications. (wikimd.org)
  • Scientists speculate that these cells along with asparaginase may be what gives the guinea pig cancer resistant properties (Sharon Vanderlip, DVM). (wikipedia.org)
  • Sequence analysis of enzymes with asparaginase activity. (ebi.ac.uk)
  • Asparaginase Activity Assay Kit (Colorimetric/Fluorometric) (ab107922) provides a simple, direct and automation-ready procedure for measuring asparaginase activity in biological samples. (abcam.com)
  • Growth of Escherichia coli A-l under aerobic conditions in an enriched medium with a total amount of 0.2 per cent glucose was biphasic and asparaginase II activity was detected after depletion of ammonia from the growth medium in the second phase of growth. (unt.edu)
  • Glucose was exhausted two hours before ammonia and three hours before asparaginase II activity was detected. (unt.edu)
  • Culture tube studies of the growth of E_j_ coli A-l in three per cent nutrient broth with varied concentrations of ammonium chloride and potassium nitrate gave lower specific activity of asparaginase II when this was compared to that seen in three per cent nutrient broth alone. (unt.edu)
  • however, addition after L-asparaginase synthesis had started did not affect the specific activity of the enzyme. (unt.edu)
  • The antitumor activity of L-asparaginase produced from the cultured cells of micro-organisms belonging to the genus Serratia is retained by a purification process wherein, as one of the steps in the purification procedure, the enzymatic liquid is heated to a temperature of at least 60* C., preferably 6070* C., thereby denaturing and rendering ineffective the L-asparaginaseinactivating factors contained in the liquid. (google.com)
  • To improve efficiency of A. niger asparaginase in application, we applied directed evolution to optimize the pH-activity profile of the enzyme. (aspergillus.org.uk)
  • Their L-asparaginase activities quantified were between 0.009 and 0.0246 M −1 mL −1 min −1 of mean L-asparaginase activity, with higher levels derived from endophytes from O. diffusa . (springer.com)
  • Has both L-asparaginase and beta-aspartyl peptidase activity. (nih.gov)
  • ASRGL1 exhibits beta-aspartyl peptidase activity consistent with plant-type asparaginases. (nih.gov)
  • Serum asparaginase activity more than 0.1 IU/mL was detected in 95%, 88%, and 7% of patients at 11, 18, and 25 days after dosing, respectively. (elsevier.com)
  • The ASRGL1 enzyme has both L-asparaginase and beta-aspartyl peptidase activity and may be involved in the production of L-aspartate, which can act as an excitatory neurotransmitter in some brain regions. (wikipedia.org)
  • Additionally, a single pretreatment dose of erythrocyte-binding asparaginase tolerized mice to multiple subsequent doses of the wild-type enzyme. (sciencemag.org)
  • The patient required tapering doses of insulin therapy for one month after the last dose of L-Asparaginase. (biomedcentral.com)